Amabily Keveny Saraiva Matsunaga

Amabily Keveny Saraiva Matsunaga

Auto-generated profile, based on publicly available information

Amabily Keveny Saraiva Matsunaga


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2024 in Revista de Gestão Social e Ambiental
Verified
Journal Article
Open access
PDF file
RCRafael Leituga de Carvalho Cavalcante
Rafael Leituga de Carvalho Cavalcante
MSMaurício Samartino
Maurício Samartino
LMLarissa Abussafi Miranda
Larissa Abussafi Miranda
JMJeniffer da Silva Alencar Mendes
Jeniffer da Silva Alencar Mendes
TTTatiana de Lima Tanaka
Tatiana de Lima Tanaka
AMAmabily Keveny Saraiva Matsunaga
Amabily Keveny Saraiva Matsunaga
Objective: The objective of this article is to conduct a comprehensive review of recent advances in understanding the pathogenesis of Alzheimer's disease (AD) and innovations in its management, emphasizing how these developments can inform more effective therapeutic strategies. Initially, this study explores contemporary findings related to the molecular and cellular mechanisms contributing to AD pathology, including the aggregation of beta-amyloid and tau, neural inflammation, synaptic dysfunction, as well as the impact of genetic and environmental factors. Theoretical Framework: Alzheimer's disease (AD) presents itself as a growing challenge for global public health, given its rising prevalence and the significant impact on the affected individuals, their families, and the healthcare systems. Method: A systematic review was conducted using major scientific databases to collect relevant articles on recent advances in the understanding and management of Alzheimer's disease, from pathogenesis to treatment. Specific keywords were used to identify studies addressing new findings and interdisciplinary therapeutic strategies. This enabled the synthesis of effective approaches and the identification of research gaps, supporting evidence-based clinical practices. Results and Discussion: Recent research has identified novel genetic markers linked to Alzheimer's disease, enhancing early diagnosis. Studies have also demonstrated the efficacy of integrated cognitive therapies in slowing disease progression. Additionally, new pharmacological treatments targeting amyloid plaques have shown promise in clinical trials. However, challenges in uniform treatment efficacy across diverse populations highlight the need for tailored therapeutic approaches.